Background: Patients hospitalised for COVID-19 may present with or acquire bacterial or fungal infections that can affect the course of the disease. The aim of this study was to describe the microbiological characteristics of laboratory-confirmed infections in hospitalised patients with severe COVID-19. Methods: We reviewed the hospital charts of a sample of patients deceased with COVID-19 from the Italian National COVID-19 Surveillance, who had laboratory-confirmed bacterial or fungal bloodstream infections (BSI) or lower respiratory tract infections (LRTI), evaluating the pathogens responsible for the infections and their antimicrobial susceptibility. Results: Among 157 patients with infections hospitalised from February 2020 to April 2021, 28 (17.8%) had co-infections (≤ 48 h from admission) and 138 (87.9%) had secondary infections (> 48 h). Most infections were bacterial; LRTI were more frequent than BSI. The most common co-infection was pneumococcal LRTI. In secondary infections, Enterococci were the most frequently recovered pathogens in BSI (21.7% of patients), followed by Enterobacterales, mainly K. pneumoniae, while LRTI were mostly associated with Gram-negative bacteria, firstly Enterobacterales (27.4% of patients, K. pneumoniae 15.3%), followed by A. baumannii (19.1%). Fungal infections, both BSI and LRTI, were mostly due to C. albicans. Antibiotic resistance rates were extremely high in Gram-negative bacteria, with almost all A. baumannii isolates resistant to carbapenems (95.5%), and K. pneumoniae and P. aeruginosa showing carbapenem resistance rates of 59.5% and 34.6%, respectively. Conclusions: In hospitalised patients with severe COVID-19, secondary infections are considerably more common than co-infections, and are mostly due to Gram-negative bacterial pathogens showing a very high rate of antibiotic resistance.

Microbiologically confirmed infections and antibiotic-resistance in a national surveillance study of hospitalised patients who died with COVID-19, Italy 2020-2021

Valeria Raparelli
Membro del Collaboration Group
;
2022

Abstract

Background: Patients hospitalised for COVID-19 may present with or acquire bacterial or fungal infections that can affect the course of the disease. The aim of this study was to describe the microbiological characteristics of laboratory-confirmed infections in hospitalised patients with severe COVID-19. Methods: We reviewed the hospital charts of a sample of patients deceased with COVID-19 from the Italian National COVID-19 Surveillance, who had laboratory-confirmed bacterial or fungal bloodstream infections (BSI) or lower respiratory tract infections (LRTI), evaluating the pathogens responsible for the infections and their antimicrobial susceptibility. Results: Among 157 patients with infections hospitalised from February 2020 to April 2021, 28 (17.8%) had co-infections (≤ 48 h from admission) and 138 (87.9%) had secondary infections (> 48 h). Most infections were bacterial; LRTI were more frequent than BSI. The most common co-infection was pneumococcal LRTI. In secondary infections, Enterococci were the most frequently recovered pathogens in BSI (21.7% of patients), followed by Enterobacterales, mainly K. pneumoniae, while LRTI were mostly associated with Gram-negative bacteria, firstly Enterobacterales (27.4% of patients, K. pneumoniae 15.3%), followed by A. baumannii (19.1%). Fungal infections, both BSI and LRTI, were mostly due to C. albicans. Antibiotic resistance rates were extremely high in Gram-negative bacteria, with almost all A. baumannii isolates resistant to carbapenems (95.5%), and K. pneumoniae and P. aeruginosa showing carbapenem resistance rates of 59.5% and 34.6%, respectively. Conclusions: In hospitalised patients with severe COVID-19, secondary infections are considerably more common than co-infections, and are mostly due to Gram-negative bacterial pathogens showing a very high rate of antibiotic resistance.
2022
Marco, Floridia; Marina, Giuliano; Monica, Monaco; Luigi, Palmieri; Cinzia, Lo Noce; Anna Teresa, Palamara; Annalisa, Pantosti; Silvio, Brusaferro; Graziano, Onder; Italian National Institute of Health Covid-Mortality Group: Luigi Palmieri, The; Agazio, Elvira; Barbariol, Pierfrancesco; Bella, Antonino; Benelli, Eva; Bertinato, Luigi; Bocci, Matilde; Boros, Stefano; Bressi, Marco; Calcagnini, Giovanni; Canevelli, Marco; Censi, Federica; Ciervo, Alessandra; Colaizzo, Elisa; Da Cas, Roberto; Del Manso, Martina; Di Benedetto, Corrado; Donfrancesco, Chiara; Fabiani, Massimo; Facchiano, Francesco; Floridia, Marco; Galati, Fabio; Giuliano, Marina; Grisetti, Tiziana; Guastadisegni, Cecilia; Lega, Ilaria; Lo Noce, Cinzia; Maiozzi, Pietro; Manno, Valerio; Martini, Margherita; Massari, Marco; Mateo Urdiales, Alberto; Mattei, Eugenio; Meduri, Claudia; Meli, Paola; Menniti Ippolito, Francesca; Minelli, Giada; Onder, Graziano; Petrone, Daniele; Pezzotti, Patrizio; Pricci, Flavia; Punzo, Ornella; Quarata, Federica; Raparelli, Valeria; Riccardo, Flavia; Rocchetto, Simone; Sacco, Chiara; Salerno, Paolo; Sarti, Giulia; Serra, Debora; Spila Alegiani, Stefania; Spuri, Matteo; Tallon, Marco; Tamburo De Bella, Manuela; Tiple, Dorina; Toccaceli Blasi, Marco; Trentin, Federica; Unim, Brigid; Vaianella, Luana; Vanacore, Nicola; Fenicia Vescio, Maria; Rocco Villani, Emanuele; Elena Weimer, Liliana; Brusaferro, Silvio
File in questo prodotto:
File Dimensione Formato  
2022_FloridiaMortalityGroup.pdf

accesso aperto

Descrizione: versione editoriale
Tipologia: Full text (versione editoriale)
Licenza: Creative commons
Dimensione 1.05 MB
Formato Adobe PDF
1.05 MB Adobe PDF Visualizza/Apri

I documenti in SFERA sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11392/2486449
Citazioni
  • ???jsp.display-item.citation.pmc??? 6
  • Scopus 8
  • ???jsp.display-item.citation.isi??? 7
social impact